MGNX - MacroGenics Shares Tumble After Reporting Adverse Events Multiple Deaths In Cancer Drug Trial | Benzinga
On Thursday, MacroGenics Inc (NASDAQ:MGNX) released interim data from the TAMARACK Phase 2 study of vobramitamab duocarmazine (vobra duo) that targets B7-H3, an antigen with broad expression across multiple solid tumors.
TAMARACK is being conducted in previously treated patients with metastatic castration-resistant prostate cancer (mCRPC).
MacroGenics shares plunged over 50% on Friday after the company reported five deaths (fatal outcome) during the trial and over 50% rate of grade 3 or worse adverse events in both dose cohorts (2 mg/kg and 2.7 mg/kg every four weeks).
On the data cut-off date of April ...